CHOSA Oncology AB
The answer first
Does CHOSA Oncology beat the market?
No, CHOSA Oncology has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 7% of Nordic stocks
- Quality59
- Value7
- Trend5
No. 172 of 195 in healthcare
Max for seven days
Follow CHOSA Oncology with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 4 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about CHOSA Oncology
Your first answer is free, no account needed.
Do you own CHOSA Oncology, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with CHOSA Oncology and a few more. Free, no card.
Super Stock+51.6%In short
- CHOSA Oncology has fallen 52.0% over the past year, including dividends.
- Overall, CHOSA Oncology ranks better than 7% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.1%. The price is 98.9% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 7% of Nordic stocks.
No. 172 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 109 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−33.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 150 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.6
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 175 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−26.1%
- 6 months−29.8%
- 9 months−29.3%
- 12 months−52.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About CHOSA Oncology
CHOSA Oncology AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 2 employees.
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.


See the full analysis of CHOSA Oncology.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card